← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
The Roskamp Institute, Inc.
$23,701,174
Total funding
26
Grants
Funding over time
peak $5.1M · FY2013–25$10M$7.5M$5M$2.5M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
DOD$23,701,174 · 26
By mechanism
—$23,701,174 · 26
Investigators at The Roskamp Institute, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
DELINEATING THE THERAPEUTIC EFFECT OF A NOVEL BBB-PENETRABLE PPAR AGONIST ON CHRONIC OUTCOMES FOLLOWING AGE-RELATED REPETITIVE MILD TBI$3,268,799
· FY2025 · Defense Health Agency
A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED CLINICAL TRIAL OF NICOTINAMIDE RIBOSIDE FOR RESTORING MITOCHONDRIAL BIOENERGETICS IN GULF WAR ILLNESS$1,626,379
· FY2020 · Defense Health Agency
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF OLEOYLETHANOLAMIDE FOR TARGETING LIPID METABOLISM IN GULF WAR ILLNESS$1,625,254
· FY2019 · Defense Health Agency
GULF WAR PESTICIDE METABOLITE MEDIATED AUTOIMMUNE DYSFUNCTION IN GULF WAR ILLNESS$1,166,397
· FY2020 · Defense Health Agency
INVESTIGATION OF MITOCHONDRIAL EPIGENETIC CHANGES AS A BIOMARKER FOR GULF WAR ILLNESS AND AN OUTCOME MEASURE IN RESPONSE TO THERAPY$1,129,681
· FY2020 · Department of the Army
DEVELOPMENT OF OLEOYLETHANOLAMIDE FOR TREATING THE CNS SYMPTOMS OF GULF WAR ILLNESS$1,119,999
· FY2018 · Department of the Army
TREATMENT STRATEGIES IN A MOUSE MODEL OF CHRONIC GULF WAR ILLNESS$956,581
· FY2017 · Department of the Army
RESTORING THE BRAIN'S LIPID HOMEOSTASIS AS A THERAPEUTIC AVENUE FOR TREATING THE CNS SYMPTOMS OF GULF WAR ILLNESS$954,000
· FY2014 · Department of Defense
VALIDATING BLOOD BIOMARKERS OF BRAIN IMMUNE AND METABOLIC DYSFUNCTION IN GULF WAR ILLNESS.$854,820
· FY2021 · Defense Health Agency
TARGETING APOE BIOENERGETICS FOR REDUCING THE RISK OF NEURODEGENERATION AFTER CHRONIC TRAUMATIC BRAIN INJURY$817,200
· FY2024 · Defense Health Agency
ALTERED BRAIN FLUID DYNAMICS AND SOLUTE ELIMINATION FOLLOWING REPETITIVE MILD TRAUMATIC BRAIN INJURY$809,258
· FY2022 · Defense Health Agency
LIPIDOMICS FOR IDENTIFYING APOE4 ASSOCIATED BIOMARKERS OF AD RELATED COGNITIVE DECLINE IN TBI$799,999
· FY2017 · Department of the Army
THE INFLUENCE OF TRAUMATIC BRAIN INJURY ON GULF WAR ILLNESS PATHOGENESIS$799,704
· FY2019 · Defense Health Agency
INFLUENCE OF APOE GENOTYPE ON TAU ELIMINATION FROM THE BRAIN IN TRAUMATIC BRAIN INJURY AND ALZHEIMER'S DISEASE.$799,450
· FY2019 · Department of the Army
NOVEL THERAPEUTIC TARGET IDENTIFICATION THROUGH ANALYSIS OF CONVERGENT AD AND TBI...$798,949
· FY2017 · Department of the Army
TAU PROCESSING BY MURAL CELLS IN TRAUMATIC BRAIN INJURY AND ALZHEIMERS DISEASE$797,495
· FY2016 · Department of the Army
BRAIN AND PLASMA MOLECULAR CHARACTERIZATION OF THE PATHOGENIC TBI-AD INTERRELATIONSHIP IN MOUSE MODELS$774,205
· FY2013 · Department of Defense
CEREBROVASCULAR DEGENERATION FOLLOWING REPETITIVE MILD TRAUMATIC BRAIN INJURY CONTRIBUTES TO TAU DEPOSITION IN THE BRAIN$749,952
· FY2022 · Defense Health Agency
IMPACT OF APOE GENOTYPE ON ASTROGLIOPATHIES IN REPETITIVE MTBI.$747,093
· FY2020 · Defense Health Agency
IDENTIFICATION OF LIPID BIOMARKERS OF INFLAMMATION AND METABOLIC DISTRURBANCES IN GWI$720,000
· FY2016 · Department of the Army